Hypertension Editors’ Picks

摘要: Pulmonary artery hypertension (PAH) is a chronic and progressive disease characterized by persistent elevation of pulmonary arterial pressure caused increased vascular resistance remodeling. The resulting right ventricular hypertrophy leads ultimately to heart dysfunction, organ failure, death. Despite extensive research over the past 2 decades aimed at development new therapies, PAH remains an incurable with high morbidity mortality. Although systemic are distinct clinical conditions, common pathophysiological processes underlie two. Therefore, many important articles focused on basic molecular mechanisms signaling pathways responsible for appear in Hypertension each year. goal, course, identify novel treatment strategies this devastating disease. Here, Editors have assembled 17 full-length related PAH, which were published our Journal 2014 2015. Potentially highlighted include microRNAs,1,2 myocardin-related transcription factor A,3 kinins,4 estradiol,5 leukotrienes,6 tumor necrosis factor-α,7 nuclear factor-κB,8 oxidative stress,9,10 TWIK-2 potassium channels,11 transient receptor potential channels.12 Two articles13,14 focus possible adverse impacts sympathetic nervous system activation known accompany PAH. studies designed improve pharmacological management using drug delivery strategies.15,16 And finally, 1 article17 describes much needed animal model investigating thromboembolic hypertension. It clear that continues be key venue exciting findings emerging from investigations into pathophysiology PAH. ### Abstract Chronic (CTEPH) entity PH not only limits patients quality life but also causes significant choice endarterectomy. However numerous …